QED is pleased to announce that it has been awarded another phase I trial from a top 5 pharmaceutical sponsor. This now brings the total to 6 phase I studies that QED has worked on for this sponsor under our MSA with them. Paul Thompson, Director Business Development for QED, said “This latest award of another important phase I study demonstrates the confidence this major pharmaceutical sponsor has in QED to deliver its early phase projects. We are looking forward to continuing our collaboration on future studies”.
Although QED has strong experience through phase I-IV, the organisation has worked extensively on early phase studies. By providing highly experienced CRAs to monitor phase I units and sites QED can offer a cost effective solution targeted to the requirements of early phase clinical research.